Navigation Links
Elcelyx Therapeutics Reports Positive Data for NewMet in Type 2 Diabetes at 2013 American Diabetes Association Scientific Sessions
Date:6/22/2013

es a model designed to predict concentrations of metformin in the blood that would occur if patients with Type 2 diabetes and mild, moderate or severe renal impairment were to take NewMet. The results of the model suggest that patients with renal impairment taking effective doses of NewMet would not have an increased risk of lactic acidosis caused by accumulation of metformin in the blood. Elcelyx will be initiating a pharmacokinetic study this summer in Type 2 diabetes patients with mild, moderate and severe renal impairment to confirm the predictions of the model.

"Metformin is the preferred initial pharmacological agent for Type 2 diabetes, but in the U.S., 40% of patients with diabetes are not taking it primarily due to issues of GI tolerability or due to the contraindication of their renal impairment. Moreover, of the 60% who are taking metformin, only about 40% are able to titrate to fully effective doses due to tolerability issues," said John Buse, M.D., Professor of Medicine and Director, Diabetes Care Center, Chief, Division of Endocrinology, Executive Associate Dean for Clinical Research at University of North Carolina School of Medicine, Chapel Hill, North Carolina. "The NewMet results to date hold the promise of addressing all these patient segments. This is very encouraging news for physicians who would like to be in compliance with ADA treatment guidelines and have their patients benefit from metformin therapy." Dr. Buse was an advisor on the Phase 2a NewMet clinical study.

To confirm results observed to date, a multicenter, double-blind dose-finding Phase 2b trial evaluating NewMet once-daily doses of 1,000, 800 and 600 milligrams compared to placebo is underway.  There are also two comparator arms with generic extended-release metformin dosed once-daily at 1,000 and 2,000 milligrams. The primary endpoint of the study is fasting plasma glucose at four weeks of treatment. Seconda
'/>"/>

SOURCE Elcelyx Therapeutics
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Elcelyx Therapeutics Names Mark Wiggins Senior Vice President of Business Development, Ginger Graham to Board of Directors
2. Elcelyx Therapeutics Completes $20 Million Series C Financing to Advance NewMet and Lovidia
3. Elcelyx Therapeutics Enrolling Phase 2b Trial of NewMet for Type 2 Diabetes
4. Cell Therapeutics, Inc. (CTI) to Report First Quarter Financial Results on April 20
5. Faruqi & Faruqi, LLP Encourages Investors Who Suffered Substantial Losses Investing in Chelsea Therapeutics International, Ltd. to Contact the Firm
6. Argos Therapeutics Secures $25 million Series D Financing to Commence Phase 3 ADAPT Study in Patients with Metastatic Renal Cell Carcinoma (mRCC) in Mid-2012
7. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
8. Zacks Industry Outlook Highlights: Eli Lilly, Forest Labs, ViroPharma, Novartis and United Therapeutics
9. Oxford BioTherapeutics Appoints Senior Industry Leader to Head its New Clinical Development Operations in Basel, Switzerland
10. Nektar Therapeutics Reports Financial Results for the First Quarter of 2012
11. Cara Therapeutics Licenses Novel Kappa Opioid Agonist, CR845, to Chong Kun Dang Pharmaceutical Corporation For South Korean Market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... , Aug. 20, 2014 Reportlinker.com announces ... in its catalogue: Global Coatings for ... This report analyzes the ... US$ Million by the following Product Segments: Active ... The report provides separate comprehensive analytics for the ...
(Date:8/20/2014)... SALT LAKE CITY , Aug. 20, 2014 /PRNewswire/ ... their revolutionary mobile diagnostic platform during a special event ... City, Utah , on September 5, 2014. The ... be LiveStreamed on the ApolloDx website, www.apollodx.com .  ... will transform diagnostic testing," said Jared Bauer , ...
(Date:8/20/2014)... , Aug. 20, 2014   Easy Breathe , the ... that its " Easy Blog " - has received more than ...   "We are thrilled that so many people are ... , CEO of Easy Breathe. "We,re committed to making sleep apnea ... Blog to stay informed about sleep apnea news , ...
Breaking Medicine Technology:Global Coatings for Medical Devices Industry 2Global Coatings for Medical Devices Industry 3Global Coatings for Medical Devices Industry 4Global Coatings for Medical Devices Industry 5Global Coatings for Medical Devices Industry 6Global Coatings for Medical Devices Industry 7Global Coatings for Medical Devices Industry 8Global Coatings for Medical Devices Industry 9Global Coatings for Medical Devices Industry 10Global Coatings for Medical Devices Industry 11Global Coatings for Medical Devices Industry 12Global Coatings for Medical Devices Industry 13Global Coatings for Medical Devices Industry 14Global Coatings for Medical Devices Industry 15Global Coatings for Medical Devices Industry 16Global Coatings for Medical Devices Industry 17Global Coatings for Medical Devices Industry 18Global Coatings for Medical Devices Industry 19Global Coatings for Medical Devices Industry 20Global Coatings for Medical Devices Industry 21Easy Breathe Blog Emerges as the Go-To Resource for Sleep Apnea Sufferers 2Easy Breathe Blog Emerges as the Go-To Resource for Sleep Apnea Sufferers 3Easy Breathe Blog Emerges as the Go-To Resource for Sleep Apnea Sufferers 4
... - Nexavar is First Approved Systemic Therapy to ... EMERYVILLE, Calif., July 23 ,Bayer HealthCare Pharmaceuticals and ... New England Journal of Medicine published,results of a ... the absolute risk of death by 31 percent ...
... FluoroPharma Inc., a company developing,breakthrough molecular imaging ... positive Phase I results for BFPET, its novel,Fluorine-18 ... second cardiovascular product to complete Phase I clinical,development., ... to assess the blood flow in the,heart (myocardial ...
Cached Medicine Technology:The New England Journal of Medicine Publishes Nexavar(R) Study Demonstrating Significant Improvement in Overall Survival in Patients With Liver Cancer 2The New England Journal of Medicine Publishes Nexavar(R) Study Demonstrating Significant Improvement in Overall Survival in Patients With Liver Cancer 3The New England Journal of Medicine Publishes Nexavar(R) Study Demonstrating Significant Improvement in Overall Survival in Patients With Liver Cancer 4The New England Journal of Medicine Publishes Nexavar(R) Study Demonstrating Significant Improvement in Overall Survival in Patients With Liver Cancer 5The New England Journal of Medicine Publishes Nexavar(R) Study Demonstrating Significant Improvement in Overall Survival in Patients With Liver Cancer 6FluoroPharma Announces Positive Phase I Safety Results for BFPET(TM), Myocardial Perfusion Imaging (MPI) Tracer for Positron Emission Tomography (PET) 2FluoroPharma Announces Positive Phase I Safety Results for BFPET(TM), Myocardial Perfusion Imaging (MPI) Tracer for Positron Emission Tomography (PET) 3
(Date:8/20/2014)... HealthDay Reporter WEDNESDAY, Aug. 20, 2014 ... group of rhesus monkeys from deadly Marburg virus, a very ... percent of those it infects, researchers report. The drug ... even when it was given three days after infection, according ... Science Translational Medicine . This is the first drug ...
(Date:8/20/2014)... time to deploy Ebola vaccines is now, Free ... now, according to a commentary being published early online ... . The authors from Yale School of Public Health ... of the current Ebola outbreak represent a public health ... efforts. Several Ebola vaccines have been developed in the ...
(Date:8/20/2014)... By Dennis Thompson ... -- Regular exercise may help older women avoid a condition ... Physically active postmenopausal women had a 10 percent lower ... more sedentary, researchers report in the Aug. 20 issue of ... Active women enjoyed this protection against the heart rhythm disorder ...
(Date:8/20/2014)... is one of the most persistent and deadliest infectious ... people each year. , Scientists who study tuberculosis have ... likely spread from humans in Africa to seals and ... and transmitted it to Native people there before Europeans ... Genomes Reveal Seals as a Source of New World ...
(Date:8/20/2014)... found a novel approach to treating cancer - using ... of Science Translational Medicine shows that cancer ... by nerves that are linked to cancer stem cells. ... Botox made the treatment cheap, safe and efficient. The ... and will soon start testing on humans. , The ...
Breaking Medicine News(10 mins):Health News:Drug for Ebola-Like Virus Shows Promise in Monkeys 2Health News:Drug for Ebola-Like Virus Shows Promise in Monkeys 3Health News:News from Annals of Internal Medicine 2Health News:Exercise May Guard Against Irregular Heartbeat in Older Women 2Health News:Exercise May Guard Against Irregular Heartbeat in Older Women 3Health News:New research shows seals and sea lions likely spread tuberculosis to humans 2Health News:New research shows seals and sea lions likely spread tuberculosis to humans 3Health News:Treating gastric cancer -- with Botox 2
... ventilators, dialysis machines, agency says safety an issue, , ... ages and medical technology improves, more people are using ... at home, adding to the need for better-educated patients. ... and Drug Administration announced Tuesday that it has started ...
... D.C. Levels of epidermal growth factor receptor (EGFR) may ... prior to their breast cancer diagnosis, according to findings presented ... 2010, held here April 17-21. The goal of the ... of the Epidemiology Program at the Fred Hutchinson Cancer Research ...
... MA and Hyde Park, NY -- Responding to the health ... department of nutrition at Harvard School of Public Health (HSPH) ... sodium reduction strategies that are strong and effectiveand that maximize ... now overwhelming evidence that we must treat sodium reduction as ...
... who metabolize nicotine slowly may need to wear nicotine patch ... New research suggests that a set length of time for ... trying to kick the habit. , Researchers at the University ... people -- about three-quarters of smokers -- break down ...
... Deepak Srivastava, MD, director of the Gladstone Institute of ... UCSF, has been elected to the American Academy of ... W. Mahley as a member of the Academy. Established ... fathers, the Academy is one of the nation,s oldest ...
... ... Incentives Are Still Available , ... (Vocus) April 20, 2010 -- Toll Brothers, the nation,s leading builder of luxury homes, ... until May 2. With the slight rise in interest rates recently, and conventional wisdom pointing ...
Cached Medicine News:Health News:FDA Tightens Oversight of Home Medical Devices 2Health News:FDA Tightens Oversight of Home Medical Devices 3Health News:Increased EGFR levels may be an early marker of breast cancer 2Health News:Experts call for accelerated national sodium reduction initiatives 2Health News:Experts call for accelerated national sodium reduction initiatives 3Health News:Experts call for accelerated national sodium reduction initiatives 4Health News:Tailored Therapy May Help More Stop Smoking 2Health News:Gladstone's Deepak Srivastava elected to the American Academy of Arts and Sciences 2Health News:Spring Into A New Toll Brothers Dream Home During the National Spring Sales Event April 24 - May 2 2Health News:Spring Into A New Toll Brothers Dream Home During the National Spring Sales Event April 24 - May 2 3Health News:Spring Into A New Toll Brothers Dream Home During the National Spring Sales Event April 24 - May 2 4
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: